{"nctId":"NCT04644484","briefTitle":"A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety","startDateStruct":{"date":"2020-09-23","type":"ACTUAL"},"conditions":["Rabies","Communicable Disease","Virus Diseases","Rhabdoviridae Infections","Mononegavirales Infections","RNA Virus Infections"],"count":1000,"armGroups":[{"label":"Experimental Group: SYN023+Rabies Vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: SYN023","Biological: Rabies Vaccine"]},{"label":"Control Group: Human Rabies Immune Globulin (HRIG)+Rabies Vaccine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Human Rabies Immune Globulin (HRIG)","Biological: Rabies Vaccine"]}],"interventions":[{"name":"SYN023","otherNames":["A Humanized Anti-Rabies Molecular antibodies cocktails"]},{"name":"Human Rabies Immune Globulin (HRIG)","otherNames":[]},{"name":"Rabies Vaccine","otherNames":["Freeze-dried Rabies Vaccine for Human Use (Vero Cells)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Is age ≥18 years, on Study Day 1 with legal identification documents, and plan to live in the local administration area during the study;\n2. Category III rabies exposure within 24 hours before Study Drug receipt ;\n3. Completed written informed consent process, and signed the informed consent forms;\n4. Subjects with the ability to understand the study procedure. And agreed to complete all follow-ups;\n5. Female subjects are not in pregnancy (with negative results of urine pregnancy tests before vaccination) and are not in the period of breast feeding, and agree to avoid pregnancy within 121 days after administration;\n6. Those who have an armpit temperature ≤ 37.0 °C.\n\nExclusion Criteria:\n\n1. Previous receipt of equine or human (rabies) globulin or rabies vaccination prior to randomization;\n2. Clinical evidence of rabies infection;\n3. Category I and Category II rabies exposure;\n4. Had fever (armpit temperature ≥ 38.5 °C) within 3 days before Study Day 1, or in the acute episode of any chronic diseases;\n5. Received immunoglobulin or blood products (except for the anti-tetanus immunoglobulin) within 43 days before Study Day 1, or plan to use any such product (except for the anti-tetanus immunoglobulin) during the study;\n6. Received systemic immunosuppressant medication such as systemic corticosteroids but not limited to systemic corticosteroids within 43 days before Study Day 1;\n7. History of any immunodeficiency disease (for example: AIDS, systemic lupus erythematosus, etc.); or Laboratory evidence of previous or current immunodeficiency disease, including, but not limited to, any laboratory evidence of HIV infection;\n8. History of spleen function deficiency or function injury, such as no spleen caused by any cause (such as splenectomy);\n9. History of any severe allergy for vaccination, such as systemic urticaria, allergic laryngeal edema, anaphylactoid purpura, local allergic necrosis (Arthus reaction), angioedema, anaphylactic shock, etc., or allergic to any ingredient of the study drug/vaccine;\n10. Previous receipt of any study product (drug, vaccine, biological product or medical device) within 6 months before Study Day 1, or plan to participate in any other clinical study during this study period;\n11. History of or clinical evidence of any systemic disease, acute disease or chronic disease (such as convulsions, epilepsy, encephalopathy, nephrotic syndrome, etc.) that the investigator considers to be likely to interfere with safety or efficacy assessment of the study;\n12. Previous medical history that may compromise the safety of the subject in the study according to the opinion of the principal investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rabies Virus Neutralizing Activity (RVNA) of Geometric Mean Concentration (GMC) at Study Day 8","description":"Rabies Virus Neutralizing Activity (RVNA) was assessed using Rapid Fluorescent Focus Inhibition Test (RFFIT).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.346","spread":null},{"groupId":"OG001","value":"0.232","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Probable or Confirmed Rabies Cases","description":"WHO's Classification of Rabies Cases:\n\n1. Suspected case: refers to a case that satisfies the definition of clinical case;\n2. Probable case: refers to a suspected case with a reliable medical history of contact with any suspected animal infected with the rabies virus;\n3. Confirmed case: refers to a suspected or probable case that is proved to be infected based on the lab test result.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Rabies Virus Neutralizing Activity (RVNA) of Geometric Mean Concentration (GMC)","description":"Rabies Virus Neutralizing Activity (RVNA) was assessed using Rapid Fluorescent Focus Inhibition Test (RFFIT).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.212","spread":null},{"groupId":"OG001","value":"0.193","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.590","spread":null},{"groupId":"OG001","value":"7.651","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.084","spread":null},{"groupId":"OG001","value":"16.003","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.023","spread":null},{"groupId":"OG001","value":"5.108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.891","spread":null},{"groupId":"OG001","value":"3.319","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.520","spread":null},{"groupId":"OG001","value":"1.645","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Rabies Virus Neutralizing Activity (RVNA) ≥0.5 IU/mL","description":"Rabies Virus Neutralizing Activity (RVNA) was assessed using Rapid Fluorescent Focus Inhibition Test (RFFIT).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"96.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":null},{"groupId":"OG001","value":"95.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null},{"groupId":"OG001","value":"81.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Efficacy Curve for the Geometric Mean Concentration (GMC) of Rabies Virus Neutralizing Activity (RVNA)","description":"Rabies Virus Neutralizing Activity (RVNA) was assessed using Rapid Fluorescent Focus Inhibition Test (RFFIT). Area Under the Efficacy Curve for the GMC of RVNA from Study Day 1 to Day 15 after administration (AUEC1-15)","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.972","spread":null},{"groupId":"OG001","value":"31.869","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":41,"n":750},"commonTop":["Administration site swelling","Administration site pain","Administration site erythema","Headache","Vaccination site pain"]}}}